Creation of an innovative and attractive training programme for prescribers to promote the correct use of fluoroquinolones (FQ)

F. Théron (1), S. Carret (1), S. Ley (2), J.Y. Chastenet (3), S. Oussèine (1), J. Niel (1)
(1) Centre Hospitalier d’Ussel, Service Pharmacie, Ussel, France ; (2) Centre Hospitalier d’Ussel, Service Maladies Infectieuses, Ussel, France ; (3) Centre Hospitalier d’Ussel, Service Qualité et Gestion des risques, Ussel, France

OBJECTIVES

→ Innovative and attractive training programme for prescribers to promote the correct use of fluoroquinolones (FQ)

METHODS

First audit in 2014 (n=47 prescriptions)
Training programme in 2016
Second audit in 2017 (n=48 prescriptions)

1h30 group session
E-learning over 3 months (a survey per month on the intranet)
Programme accredited « Continuous Professional Development »

TRAINING PROGRAMME

✓ The group session : 65% of participation
✓ E-learning : 7 physicians (participated at all e-learning)
✓ Evaluation (note):

Before After
Group session 4/9 8/9
(n=33)
E-learning 6/10 8/10
✓ Satisfaction : 😊
All of participants found this training useful

RESULTS

Year 2014 2017
Duration (days) 43 77
Number of prescriptions 47 48

Percentages of conformity

<table>
<thead>
<tr>
<th>Criterion</th>
<th>2014</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>60%</td>
<td>80%</td>
</tr>
<tr>
<td>B</td>
<td>47%</td>
<td>63%</td>
</tr>
<tr>
<td>C</td>
<td>63%</td>
<td>67%</td>
</tr>
<tr>
<td>D</td>
<td>72%</td>
<td>77%</td>
</tr>
<tr>
<td>E</td>
<td>50%</td>
<td>30%</td>
</tr>
<tr>
<td>Global Conformity</td>
<td>15%</td>
<td>18%</td>
</tr>
</tbody>
</table>

AUDITS

Increase in the duration of the 2017’s audit compared to 2014’s audit (for a similar number of prescriptions) → in the use of fluoroquinolones of 43% in 2017

Repartition of infections treated with FQ in the 2 audits

Increase in the percentage of global conformity → improvement of practices

CONCLUSIONS-DISCUSSION

• This initiative, conducted by a chemist, a physician specialized in infectious diseases and a quality expert, has led to the development of training for prescribers combining traditional and digital tools.
• Valorization in a "Continuing Professional Development Programme" is a real argument which attracts more participants and allows sustainability of this project.
• Furthermore, the warning issued by the European Medicines Agency of potentially permanent side effects of quinolone and fluoroquinolone antibiotics is an argument to pursue this training programme, in order to restrict the prescriptions.

ACKNOWLEDGEMENTS-REFERENCES


24th Congress of the EAHPP - 27, 28, 29 March 2019 – Barcelona

Abstract number: 4CP5-075
ATC code: J01 - Antibacterials for systemic use